Latvian pharmaceutical firm Grindex, the producer of Meldonium, is struggling with the World Anti-Doping Agency (WADA) for the drug's exclusion from the list of prohibited substances, Grindex spokeswoman Laila Klavina said on Thursday.
The drug Meldonium, also known as Mildronate, was included in the list of preparations banned by the WADA from January 1, 2016, reports Tass.
"We're struggling for excluding Mildronate from the list of prohibited substances," Klavina said.
"We communicated with WADA representatives, provided all arguments and facts, research data to exclude Mildronate from the list of prohibited substances. The discussion is open to this day. The company will be doing everything possible to return the preparation to the category of allowed substances," the Grindex spokeswoman said.
The company's dialogue with the WADA stays outside the realm of judicial proceedings, she said. "This is not an issue of court proceedings because in this case we would have acted differently. Now we're working in compliance with all the juridical procedures prescribed for this situation," she added.
The drug Meldonium was included in the list of preparations banned after which several Russian athletes tested positive for the banned substance.
The presence of this formula in the athlete's blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
Those who have proved to have used meldonium since are cyclist Eduard Vorganov, figure skater Yekaterina Bobrova, tennis player Maria Sharapova, skater Pavel Kulizhnikov, short-track skaters Semion Elistratov and Ekaterina Konstantinova, volleyball player Aleksandr Markin and biathlete Eduard Latypov.
Meanwhile, Grindex said on its website on Wednesday that "Mildronate is widely used in the clinical practice. During increased physical activity, it restores the oxygen balance of tissue cells as well as it activates the metabolic processes that results in lower requirements of oxygen consumption for energy production. Mildronate is widely recognized by health care professionals and patients, and this may include athletes as well.".
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
